Targeting Sorafenib-Resistant Hccs: a Novel T Cell Immunotherapeutic Strategy with in Situ Injectable Thermosensitive Peg-Plga- Coated Igf1r/Cd3 Bispecific Antibody and Preclinical 3d Organoid Model (1/3)

Project: A - Government Institutionb - Ministry of Science and Technology

Project Details

Description

本計畫將針對雷沙瓦抗藥性肝細胞癌 (Sorafenib-resistant HCC),以3D腫瘤類器官為模式,發展一新穎結合可注射熱敏性水膠 PEG-PLGA- coated X 蛋白/CD3 雙功能抗體武裝免疫T細胞療法與免疫檢查點抑制劑(immune checkpoint blockade anti-PDL1 Ab atezolizumab),精準治療雷沙瓦抗藥性肝細胞癌,並進一步提供克服雷沙瓦耐藥性癌症治療的科學依據。
StatusActive
Effective start/end date8/1/227/31/23

Keywords

  • 3D tumor organoid
  • sorafenib-resistant HCC
  • insulin-like growth factor receptor 1 (IGF-1R)
  • IGF-1R/CD3 Bispecific Ab Arm T cell
  • in situ injectable thermosensitive PEG-PLGA- coated IGF1R/CD3 BsAb Arm T